CPC Pursues Development of Proprietary Synthetic Sealants as part of MedClose(TM) Global Commerc...(s which may include sealing of femoral a...),Health

Date:3/10/2009

s, which may include sealing of femoral arteriotomy closures, biopsies and vertebral bodies following transpedicular interventions. They may also include the sealing of difficult-to-control bleeding sites during surgery - such as cardiac, lung, liver, pancreas, and OB/GYN procedures."

About CPC

CPC of America develops therapeutic devices for use in endovascular procedures. CPC's current focus is the completion of development and testing of the MedClose(TM) vascular closure system, an internal puncture-closing system for use in catheter laboratories.

Forward Looking Statements

The statements contained in this press release that are not historical are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including statements, without limitation, regarding the Company's expectations, beliefs, intentions or strategies regarding the future. Such forward-looking statements relate to, among other things: (1) the Company's continuing development of its MedClose(TM) vascular closure system, (2) the Company's expectations concerning regulatory approvals of the MedClose system and the commencement of revenue producing operations based on the sale or licensing of the MedClose, (3) the Company's intentions and expectations concerning the development of proprietary synthetic sealants as part of its global commercialization strategy for MedClose, and (4) the commencement of manufacturing of the MedClose system. These statements are qualified by important factors that could cause the Company's actual results to differ materially from those reflected by the forward-looking statements.

Such factors include but are not limited to: (1) the Company's ability to finance the continued development and commencement o
'/>"/>

SOURCE CPC of America, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine news :

1. Encision Pursues Transfer of Quotation to OTC Bulletin Board
2. Haemacure Confirms Operation Qualification of Production Equipment and Pursues Milestone Payment from CSL
3. BPO Management Services Pursues Eligibility for OTC BB
4. Isolation of a new gene family essential for early development
5. Therap Services Continues to Hire Experienced Developmental Disability Industry Clinicians for its Customer Support Team
6. The Philadelphia Walk Now for Autism Expected to Draw 10,000 Walkers and Raise $1 Million to Help Find Answers About the Nations Fastest-Growing Developmental Disorder
7. Ovation further advances development pipeline with new phase III epilepsy study
8. Pioneer Surgical Technology Hires Vice President of New Business Development
9. Bridgetech Announces Addition of the Agency for Healthcare Research and Quality as Content Provider in its Development of a Healthcare Web Portal in China
10. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
11. DTI Medical Corporation Announces Reverse Split and Other Corporate Developments